Stock ALA AROVELLA THERAPEUTICS LIMITED
Add to a list
To use this feature you must be a member
Log inSign up

All News Arovella Therapeutics Limited

Equities

ALA

AU0000182784

Market Closed - Australian S.E.
Other stock markets
 02:10:07 2024-06-26 EDT 		5-day change 1st Jan Change
0.145 AUD +11.54% Intraday chart for Arovella Therapeutics Limited +16.00% +26.09%
06-13 Arovella Therapeutics, Teva Pharmaceuticals End ZolpiMist License Agreement MT
06-05 Arovella Therapeutics Completes Process Development for ALA-101 Manufacturing; Shares Jump 9% MT

All News

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Arovella Therapeutics, Teva Pharmaceuticals End ZolpiMist License Agreement
MT
Arovella Therapeutics Completes Process Development for ALA-101 Manufacturing; Shares Jump 9%
MT
Arovella Therapeutics Receives Firm Commitments for About AU$12.5 Million Raise
MT
Arovella Therapeutics' ALA-101-onCARlytics Collaboration with Imugene Ends; Shares Down 12%
MT
Arovella Therapeutics Limited Reports Earnings Results for the Half Year Ended December 31, 2023
CI
Arovella Boosts Solid Tumor Pipeline with Novel CAR-iNKT Cell Armouring Tech License
MT
Arovella Therapeutics Manufactures GMP-Grade Lentiviral Vector for Cancer Therapy Product; Shares Climb 4%
MT
Arovella Therapeutics Ltd. Announces Change of Company Address
CI
Arovella Therapeutics Appoints CFO
MT
Arovella Therapeutics Limited Announces Changes to its Board
CI
Arovella Therapeutics Limited Announces Executive Changes
CI
Arovella Therapeutics Secures AU$2 Million Tax Rebate for Fiscal Year 2023
MT
Australian Shares Flat With Positive Bias Amid Hopes of US Fed Keeping Rates Steady
MT
Arovella Therapeutics Secures License for Tumor Targeting Antibody; Shares Fall 6%
MT
Arovella Therapeutics Limited Announces Retirement of David Simmonds as Non-Executive Director
CI
Arovella Therapeutics Limited Reports Earnings Results for the Full Year Ended June 30, 2023
CI
Arovella Therapeutics Raises AU$2.2 Million From Oversubscribed Share Purchase Plan
MT
Arovella Therapeutics Extends Closing Date of Share Purchase Plan
MT
Arovella Therapeutics, UNC Further Discussions on Enhanced iNKT Cells Performance
MT
Arovella Therapeutics focused on driving ALA-101 into the clinic
AQ
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. ALA Stock
  4. News Arovella Therapeutics Limited